NEWS
New mRNA vaccine for mpox being tested in the UK
A new mpox vaccine is being tested in the UK, as the virus continues to spread in many parts of the world. The mPower trial is testing the effectiveness of an investigational mRNA vaccine for mpox. The study is delivered by NIHR Clinical Research Network (CRN) and sponsored by Moderna. Since 2022 there has been an increased transmission of mpox in the UK. Mpox is spread through physical contact with someone who is currently infected. Anyone can get mpox, but cases in the UK have so far been predominantly in gay, bisexual and other men who have sex with men (GBMSM).
Mpox cases have significantly declined in the UK thanks to public health measures including the rapid rollout of vaccines by the NHS and sexual health services and a campaign geared towards mpox awareness and behavioural change. But the virus has continued to spread and remains a public health threat globally. In the UK and Europe there is only one vaccine licensed for
IVD solutions through partnership
MASTDISCS®
AST, Resistance Marker and Identification Discs in Cartridges
• Premium quality products
immunisation against mpox. The mPower Trial is being undertaken as part of the Moderna-UK Strategic Partnership. This partnership is bringing mRNA vaccine manufacturing to the UK and building resilience to future health emergencies. Researchers from University Hospitals Bristol and Weston NHS Foundation Trust are currently recruiting volunteers to the study, with plans to complete enrolment in April.
Potential novel biomarkers of coronary heart disease discovered
Researchers at the German Center for Diabetes Research (DZD), Helmholtz Munich, and Ludwig-Maximilians-University Munich (LMU) have identified novel protein biomarkers that are associated with the development of coronary heart disease (CHD) in people with and without diabetes. Coronary heart disease is one of the most common causes of death worldwide, especially in Europe where it is responsible for nearly half of all deaths. Among middle-aged adults, individuals with type 2 diabetes (T2D) have a two to four times higher risk of developing CHD than people without T2D. The research team investigated the predictive performance of protein biomarkers on incident CHD in individuals with and without T2D. For their study, published in
Cardiovascular Diabetology, the researchers used data from Cooperative Health Research in the Region of Augsburg (KORA). The validation cohort included 888 participants from the KORA-Age1 study with 70 incident cases of CHD (19 vs. 51 cases in the group with T2D and without T2D, respectively) during 6.9 years of
follow-up. They tested blood samples of the subjects for 233 plasma proteins related to cardiovascular disease and inflammation. The researchers thus identified two
proteins associated with incident CHD in individuals with diabetes and 29 proteins in those without baseline T2D. Six of these are novel candidates for incident CHD. The results of this study contribute significantly to a better understanding of the pathophysiology of CHD in T2D patients and offer potential new approaches to the prevention and treatment of this serious complication. They underscore the importance of further research in this area and the role of the German Center for Diabetes Research in resolving pressing issues related to diabetes and its complications. n Luo H, Huemer MT, Petrera A et al. Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population- based KORA study. Cardiovasc Diabetol. 2024 Feb 3; 2 3 (1): 53. doi:10.1186/ s12933-024-02143-z
WWW.PATHOLOGYINPRACTICE.COM APRIL 2024
• Compatible with EUCAST and CLSI standards
• Bespoke service available
• 4 weeks stability in MAST®
DISCMASTER
Contact us on
sales@mast-group.com
9
NIAID
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57
